Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.

Expert Review of Hematology
Massimo BrecciaRobin Foà

Abstract

Introduction: Tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity, have significantly prolonged the overall survival of patients affected by chronic myeloid leukemia (CML) and changed drastically the outcome. Evidences from several studies suggest that in patients who have achieved a sustained, stable and deep molecular response, TKI treatment can be safely discontinued with a close subsequent monitoring. Thus, a stable deep molecular response (DMR) has become a feasible treatment goal in CML. Areas covered: In this review, the main findings extrapolated from sponsored and real-life evidences regarding TKI discontinuation were discussed, through a broad research on Medline, Embase and archives from EHA and ASH congresses (including words such as discontinuation, treatment-free remission, TFR, etc). Moreover, suggestions emerged from international guidelines about treatment-free remission (TFR) are presented. Expert opinion: With the growing availability of clinical trials and real-life data on TFR, in recent years the possibility of offering to CML patients a safe, informed and shorter path to TFR, through the achievement of a stable deep molecular response (DMR), has become an increasing option. However, m...Continue Reading

References

Dec 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe RousselotFrançois-Xavier Mahon
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johan RichterLeif Stenke
Jul 17, 2015·American Journal of Hematology·Silvia MoriCarlo Gambacorti-Passerini
Nov 21, 2015·American Journal of Hematology·Carlo Gambacorti-PasseriniRocco Piazza
Jan 16, 2016·American Journal of Hematology·Elias Jabbour
Mar 26, 2016·Blood·Timothy P Hughes, David M Ross
Jun 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hannah BowerTherese M-L Andersson
Dec 10, 2016·Blood·Delphine ReaUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel EtienneFrançois-Xavier Mahon
Dec 10, 2017·Hematology·Francois-Xavier Mahon
Nov 6, 2018·American Journal of Hematology·Jorge CortesJeffrey H Lipton
Dec 7, 2018·Blood Cancer Journal·Juan Carlos Hernández-BoludaUNKNOWN Grupo Español de Leucemia Mieloide Crónica (GELMC)
Jul 5, 2019·British Journal of Haematology·Marc G BergerUNKNOWN (France Intergroupe des Leucémies Myéloïdes Chroniques)
Jul 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Franck Emmanuel NicoliniFrançois-Xavier Mahon
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HochhausUNKNOWN ESMO Guidelines Committee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.